Phytonadione
Product Images NDC 52584-043

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Phytonadione (NDC 52584-043). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by General Injectables & Vaccines, Inc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Formula1.jpg (Formula1)

Chemical structure of the active ingredient in PHYTONADIONE by General Injectables & Vaccines, Inc. The diagram depicts the molecular structure with carbon, hydrogen, and oxygen atoms arranged in a complex chain featuring a cyclic component and multiple double bonds, labeled as the E component.*

FDA Label Image

Image1.jpg (Image1)

An instructional diagram showing step-by-step usage directions for a vial and injector device. It includes illustrations on removing protective caps, aligning and threading the vial onto the injector, flipping down the needle shield, removing the needle cover, and activating the needle shield after injection with a firm press to hear an audible click.*

FDA Label Image

Image2.jpg (Image2)

Illustrated user guide for IMS Saf-T-Jet Safety Needle, demonstrating step-by-step aseptic technique for assembly and injection use, including positioning, locking the needle shield, and proper disposal in an approved sharps container.*

FDA Label Image

Label1.jpg (Label1)

Label for PHYTONADIONE injectable emulsion, USP, 1 mg per 0.5 mL dose, distributed by General Injectables & Vaccines, Inc. The label includes storage instructions, a barcode, and prescription-only status. It notes no preservatives added and specifies use for intramuscular or subcutaneous injection with a neonatal concentration.*

FDA Label Image

Table1.jpg (Table1)

Dosage information for PHYTONADIONE covering treatment of hemorrhagic disease in newborns, including prophylaxis and treatment doses, and initial adult dosages for anticoagulant-induced prothrombin deficiency and hypoprothrombinemia caused by various factors.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.